This article was originally published Aug. 1.

PathoGenetix has raised $4 million in the first closing of a Series B financing round and has received $9.5 million in commitments for the round from investors, the Woburn, Mass.-based company said this week.

Excel Venture Management led the financing, which also included CB Health Ventures, HealthCare Ventures, and other investors who participated in the firm's 2010 Series A financing round, during which it raised $1.3 million.